Physician profile
Slamat Ali
NPI 1851546121
$6,738.42
in general payments reported to CMS, 2019-2025
29 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $1,328 · 2021: $146 · 2022: $1,124 · 2023: $1,393 · 2024: $1,166 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,709 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,709.35 |
| Education | $113.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,576.54 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $692.91 | 2022-2025 | Benlysta, Jesduvroq |
| Amgen INC. | $588.29 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Fresenius USA Marketing, INC. | $586.47 | 2021-2025 | Velphoro, Velphoro |
| Ani Pharmaceuticals, INC. | $542.47 | 2023-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $448.14 | 2022-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $304.82 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $290.37 | 2022-2025 | |
| Ardelyx, INC. | $225.93 | 2023-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $215.57 | 2022-2025 | Jynarque |
| Vifor Pharma, INC. | $188.53 | 2022-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $152.75 | 2023-2025 | Acthar |
| Travere Therapeutics, INC. | $143.21 | 2023-2025 | |
| Daiichi Sankyo INC. | $133.38 | 2022-2025 | Injectafer |
| Calliditas Therapeutics US INC. | $133.37 | 2024-2025 | Tarpeyo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $89.07 | 2025 | Ozempic |
| Abiomed | $75.86 | 2024-2025 | Impella |
| Baxter Healthcare | $74.19 | 2019 | |
| Kyowa Kirin, INC. | $55.92 | 2024-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $49.13 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $48.16 | 2022-2024 | Rayaldee |
| Akebia Therapeutics INC | $32.88 | 2022-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.64 | 2024 | Jardiance |
| Genentech USA, INC. | $22.76 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.13 | 2022 | |
| Scpharmaceuticals INC. | $18.93 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Slamat Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.